IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5%.

Trial Profile

IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5%.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Tafluprost/timolol (Primary)
  • Indications Open-angle glaucoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Status changed from recruiting to discontinued.
    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top